The Miami Entrepreneur

Eli Lilly’s new diabetes drug continues to show promise as an obesity treatment

Read Time:7 Second

Eli Lilly continues to work on commercializing its strong innovation pipeline, which is a key reason the CNBC Investing Club owns the stock.

About Post Author

Happy
Happy
0 %
Sad
Sad
0 %
Excited
Excited
0 %
Sleepy
Sleepy
0 %
Angry
Angry
0 %
Surprise
Surprise
0 %
Previous post Lyft plans to build a hybrid network of autonomous and driver vehicles, co-founder says
Next post Casey’s increases dividend, says pizza, breakfast items made for ‘strong’ sales